Search research articles
Contact Us
Filters
Showing results (21-30 of 78) with videos related to
Page
of 8
Sort By:
Breast Cancer Research : BCR
|
September 3, 2011
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Catherine Huang, Catherine C Park, Susan G Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2023
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
Grazia Arpino, Juan de la Haba Rodríguez, Jean-Marc Ferrero, et al.
Advances in Therapy
|
March 17, 2026
Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative
Sean Khozin, Nancy A Dreyer, Dominic Galante, et al.
Cancer Research Communications
|
August 17, 2023
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
Junkai Wang, Alexander B Saltzman, Eric J Jaehnig, et al.
Breast Cancer Research and Treatment
|
June 21, 2019
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia
Polly Niravath, Susan G Hilsenbeck, Tao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2010
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts
Mothaffar F Rimawi, Lisa S Wiechmann, Yen-Chao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006
Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2016
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
Zahi Mitri, Rita Nanda, Kimberly Blackwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2014
Circulating tumor cell analysis in metastatic triple-negative breast cancers
Mark Jesus M Magbanua, Lisa A Carey, Amy DeLuca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2010
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy
Beate C Litzenburger, Chad J Creighton, Anna Tsimelzon, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 78) with videos related to
Sort By:
Page
of 8
Breast Cancer Research : BCR
|
September 3, 2011
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Catherine Huang, Catherine C Park, Susan G Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2023
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
Grazia Arpino, Juan de la Haba Rodríguez, Jean-Marc Ferrero, et al.
Advances in Therapy
|
March 17, 2026
Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative
Sean Khozin, Nancy A Dreyer, Dominic Galante, et al.
Cancer Research Communications
|
August 17, 2023
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
Junkai Wang, Alexander B Saltzman, Eric J Jaehnig, et al.
Breast Cancer Research and Treatment
|
June 21, 2019
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia
Polly Niravath, Susan G Hilsenbeck, Tao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2010
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts
Mothaffar F Rimawi, Lisa S Wiechmann, Yen-Chao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006
Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2016
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
Zahi Mitri, Rita Nanda, Kimberly Blackwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2014
Circulating tumor cell analysis in metastatic triple-negative breast cancers
Mark Jesus M Magbanua, Lisa A Carey, Amy DeLuca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2010
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy
Beate C Litzenburger, Chad J Creighton, Anna Tsimelzon, et al.
Page
of 8